Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study assessed the effect on asthma control of different dose levels and regimens of
QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2
agonist medication. Safety was assessed also. Comparison was to placebo and omalizumab.
Information from this study was planned to support the design of future studies.